Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Broadcom Inc (AVGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Broadcom Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Broadcom Inc trades at $421.55 (market cap $1.98T). The key difference: Broadcom Inc is far larger — about 390.5× ACADIA Pharmaceuticals Inc.'s market cap, and Broadcom Inc pays a 0.62% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | AVGO | |
|---|---|---|
Market Cap | $5.07B | $1.98T |
Sector | Health | Technology |
52-Week High | $29.41 | $481.57 |
52-Week Low | $20.06 | $289.60 |
Enterprise Value | $4.19B | $2.02T |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Broadcom (AVGO) trades at $422.4, down 1.25% on the day, but maintains a bullish technical trend with strong support at $418. The company reported robust earnings, beating estimates for three consecutive quarters, with Q1 2026 EPS of $2.44 exceeding the $2.40 forecast. Revenue growth accelerated to $63.89 billion in 2025, up from $51.6 billion in 2024, while net income surged to $23.13 billion. Valuation multiples remain elevated with a P/E of 69.23, reflecting high investor expectations for AI-driven growth.
Outlook remains positive given strong AI revenue projections exceeding $100 billion by 2027, but high valuation and dependence on a few large customers pose risks. Analyst consensus is overwhelmingly bullish with 86% buy ratings and a $510.21 price target, suggesting 21% upside. Competitive pressures in the semiconductor space and macroeconomic volatility are key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →
